Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Marketbeat.com reports.

SANA has been the topic of a number of other reports. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a report on Wednesday, November 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Stock Up 160.6 %

Sana Biotechnology stock opened at $4.30 on Wednesday. The stock has a 50-day simple moving average of $2.39 and a 200 day simple moving average of $4.07. The stock has a market capitalization of $960.06 million, a price-to-earnings ratio of -3.07 and a beta of 1.45. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. As a group, sell-side analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the third quarter worth $29,000. Barclays PLC boosted its holdings in Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after buying an additional 178,179 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth about $45,000. Finally, State Street Corp increased its stake in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after acquiring an additional 269,274 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.